Key Points
- CEO Vlad Vitoc bought 10,500 shares on Nov. 25 at an average price of $0.97 (total $10,185), increasing his direct stake to 831,421 shares — a 1.28% rise in ownership.
- MAIA shares jumped about 11.3% (opened $1.18) while the company — market cap roughly $43.7M — reported a quarterly EPS of ($0.27) that missed estimates and is a clinical‑stage biotech with lead candidate THIO in Phase II for non‑small cell lung cancer.
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) CEO Vlad Vitoc acquired 10,500 shares of the stock in a transaction dated Tuesday, November 25th. The stock was acquired at an average price of $0.97 per share, for a total transaction of $10,185.00. Following the purchase, the chief executive officer directly owned 831,421 shares in the company, valued at approximately $806,478.37. This trade represents a 1.28% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.
MAIA Biotechnology Trading Up 11.3%
Shares of NYSEAMERICAN MAIA opened at $1.18 on Friday. MAIA Biotechnology, Inc. has a 12-month low of $0.87 and a 12-month high of $2.74. The firm has a market capitalization of $43.70 million, a price-to-earnings ratio of -1.62 and a beta of -0.01. The firm has a 50 day moving average of $1.33 and a 200 day moving average of $1.57.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.08). Sell-side analysts predict that MAIA Biotechnology, Inc. will post -1.3 EPS for the current year.
Hedge Funds Weigh In On MAIA Biotechnology
Several institutional investors and hedge funds have recently bought and sold shares of MAIA. Centerpoint Advisory Group bought a new stake in MAIA Biotechnology during the second quarter valued at about $28,000. Marshall Wace LLP bought a new position in shares of MAIA Biotechnology in the second quarter worth about $29,000. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology during the 2nd quarter valued at about $52,000. Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Finally, Centric Wealth Management grew its stake in shares of MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company's stock valued at $1,032,000 after acquiring an additional 505,150 shares during the period. 5.65% of the stock is currently owned by hedge funds and other institutional investors.
MAIA Biotechnology Company Profile
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
